Topiramate Is Safe for Refractory Neonatal Seizures: A Multicenter Retrospective Cohort Study of Necrotizing Enterocolitis Risk - 18/03/22
Abstract |
Background |
A previously published, single-institution, case series suggested an association between topiramate administration in neonates and subsequent development of necrotizing enterocolitis (NEC). This contradicted our more extensive experiences using topiramate in this population. We therefore studied safety and tolerability of topiramate for treating refractory neonatal seizures, hypothesizing that the risk of developing NEC following topiramate exposure was low and that most infants tolerate topiramate.
Methods |
This multicenter retrospective cohort study included seventy-five neonates who received topiramate to treat seizures from January 2011 to October 2019 at three geographically diverse level IV neonatal intensive care units affiliated with pediatric tertiary hospitals. Data included demographics, birth history, seizure etiology, treatment response, side effects, and occurrence and details of NEC.
Results |
Three of seventy-five infants (4%) developed NEC following topiramate exposure. These infants did not differ in gestational age, birth weight, seizure etiology, postmenstrual age, weight when topiramate was initiated, or dosing of topiramate. Topiramate was well tolerated. Only three infants (4%) discontinued due to side effects. The most common side effect (20%) was weight loss (typically <5%). Topiramate was felt to be efficacious (61%). Most infants (72%) continued topiramate when discharged.
Conclusions |
Our multicenter, 75-infant study demonstrated that development of NEC after treatment with topiramate was rare (4%) and refutes prior literature suggesting an association. Topiramate was felt to be efficacious and was well tolerated. Although limited by retrospective design, study data are broadly applicable and support thoughtful use of topiramate as a safe, reasonable option for treating refractory neonatal seizures.
Le texte complet de cet article est disponible en PDF.Keywords : Acute symptomatic seizures, Neonatal seizures, Medication side effects, Topiramate
Plan
Conflict of interest and source of funding statement: The authors have no potential, perceived, or real conflicts of interest to report relative to this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Study design, collection, analysis and interpretation of data, and all subsequent writing as well as decisions on manuscript submission were made at authors' discretion without undue influence. Drafting and revision of manuscript was performed by all study authors without honorarium, grant, or other form of payment. |
|
Presentation of study data in other venues: Data from this study have been accepted for presentation as a virtual poster at the Child Neurology Society Meeting 2021 and were also presented as a poster at the Virtual Pediatric Academic Society (PAS) Meeting 2021. |
Vol 129
P. 7-13 - avril 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?